The t(12;21) translocation, generating the TEL/AML1 fusion protein, is the most common genetic lesion in childhood cancer. Using a bone marrow transplantation model, we demonstrate that TEL/AML1 expression impinges on normal hematopoietic differentiation, leading to the in vivo accumulation and persistence of an early progenitor compartment with a Sca1 þ /Kit hi /CD11b þ phenotype and an increased self-renewal capacity, as documented by replating assays in vitro. Differentiation of these cells is not blocked, but the frequency of mature blood cells arising from TEL/AML1-transduced progenitors is low. Impaired differentiation is prominently observed in the pro-B-cell compartment, resulting in an proportional increase in early progenitors in vivo, consistent with the t(12;21) ALL phenotype. Despite the accumulation of both multipotent and B-cell progenitors in vivo, no leukemia induction was observed during an observation period of over 1 year. These results are consistent with findings in twins with concordant ALL, showing that TEL/AML1 generates a preleukemic clone in utero that persists for several years in a clinically covert fashion. Furthermore, our studies showed that the pointed domain of TEL/AML1, which recruits transcriptional repressors and directs oligomerization with either TEL/ AML1 or wild-type TEL, was essential for the observed differentiation impairment and could not be replaced with another oligomerization domain.
Introduction
RUNX1 is one of the most frequently mutated genes in human acute leukemias and hematopoietic disorders. In total, 20% of pediatric B-cell acute lymphoblastic leukemias (ALL) carry the t(12;21), juxtaposing the RUNX1 gene on chromosome 21 with the ETV6 gene on chromosome 12 (Shurtleff et al., 1995; Borkhardt et al., 1997) . RUNX1 is also directly targeted by several chromosomal translocations in acute myelogenous leukemia (AML), with the t(8;21) being the most common, occurring at a frequency of approximately 15%. In addition to translocations, inactivating or dominant-negative mutations in the RUNX1 gene have been identified in minimally differentiated M0-AML, myelodysplastic syndromes associated with AML development, and in pedigrees of familial platelet disorder with a propensity to develop AML (FPD-AML syndrome) (Osato, 2004) . Importantly, based on studies of clinical samples and animal models, it is now generally accepted that these genetic alterations establish a preleukemic clone, but require secondary events to provoke an overt leukemia (Speck and Gilliland, 2002; Greaves et al., 2003) . However, the mechanism by which the different RUNX1 alterations induce a preleukemic stage and why distinctive disease phenotypes arise is poorly understood.
RUNX1 encodes a protein generally called AML1, which is a member of the heterodimeric core-binding factor (CBF) family of transcription factors. AML1 has been shown to regulate a number of genes relevant to myeloid and lymphoid development (Tenen et al., 1997; Licht, 2001) , which is reflected in the perturbation of adult hematopoiesis at several different levels in runx1-deficient mice (Ichikawa et al., 2004; Sun and Downing, 2004; Growney et al., 2005) . DNA binding occurs through the conserved Runt homology domain (RHD) in the N-terminal half and is enhanced by interaction with the CBF b-subunit (Meyers et al., 1993) , whereas the C-terminal portion contains multiple binding domains for transactivators and repressor complexes (Kitabayashi et al., 1998; Levanon et al., 1998; Fenrick et al., 1999) . Significantly, recruitment of the AML1 complex to gene enhancers can occur through direct DNA-binding or via protein-protein interactions (Pabst et al., 2001) .
Interestingly, both the t(12;21) associated with B-cell ALL and the AML-associated t(8;21) fuse AML1 with a transcriptional repressor, with the net result being the active inhibition of AML1-regulated promoters Zelent et al., 2004) . However, whereas the t(8;21) fusion product AML1/ETO contains only the N-terminal portion of AML1 encompassing the RHD (Erikson et al., 1992; Miyoshi et al., 1993) , the t(12;21) fusion protein TEL/AML1 includes almost the fulllength AML1, containing both the RHD and C-terminal transactivating and repressor domains (Golub et al., 1995; Romana et al., 1995) . The ETV6 gene, encoding the TEL ets-transcription factor, drives expression of TEL/AML1 and provides the N-terminal portion, including the pointed domain (PTD) of TEL, which has been shown to mediate oligomerization (Jousset et al., 1997) . Oligomerization has been shown to be necessary for repressor function, possibly by enhancing recruitment of corepressors or histone deacetylases (Fenrick et al., 1999; Lopez et al., 1999) , but may also contribute to TEL/AML1 activity by sequestering wt TEL (McLean et al., 1996) . Thus, in addition to being differentially expressed, distinct features of the fusion proteins themselves may determine their oncogenic potential by influencing not only the nature and quantity of transcriptional regulators recruited to target genes but also the spectrum of genes deregulated.
The importance of distinct intrinsic functions of the TEL/AML1 and AML1/ETO fusion proteins in disease specificity can be evaluated by comparing the consequence of expression in multipotent hematopoietic cells. We and others have recently demonstrated that expression of AML1/ETO in murine hematopoietic progenitors has a profound effect on the proliferation and differentiation capacity of the myeloid compartment in vivo, consistent with its association with AML, although more subtle effects were also observed in terminal stages of Band T-cell differentiation (Yuan et al., 2001; de Guzman, 2002; Higuchi et al., 2002; Schwieger et al., 2002) . The subsequent analysis of adult hematopoiesis in runx1-deficient mice showed overlapping but distinct phenotypes (Ichikawa et al., 2004; Sun and Downing, 2004; Growney et al., 2005) , demonstrating functional differences between AML1/ETO expression and Runx1 loss.
The goal of this study was to determine the effect of TEL/AML1 expression on myeloid and lymphoid development using the same conditions as used for AML1/ETO, to provide insight into how TEL/AML1 may induce a protracted preleukemic state and why this translocation is normally associated with ALL. In addition, we initiated experiments to determine the functional domains of TEL/AML1-mediated transformation by evaluating the importance of the PTD in TEL. Our results provide evidence that innate functional properties of TEL/AML1 are responsible for establishing a preleukemia with a propensity for B-cell transformation and demonstrate the importance of the PTD domain in this function.
Results

Transduction and transplantation of bone marrow (BM) cells with enhanced green fluorescent protein (eGFP) and TEL/AML1-expressing vectors
To direct expression of TEL/AML1 into early progenitor compartments, we used the FMEV retroviral vector to generate FMEV-T/A (Figure 1a) . The FMEV vectors coexpresses the eGFP, which allows easy detection, isolation, and analysis of infected cells. In order to test the importance of the PTD domain in TEL/AML1, a second vector was generated (FMEV-TSw/A), in which the PTD domain was 'swapped' with the unrelated coiled-coiled domain of Epstein-Barr virus encoded EB1/Zebra. Previous studies have demonstrated that this domain can self-associate and functionally replace PTD without complete loss of TEL repressor activity, but can no longer oligomerize with wt TEL (Lopez et al., 1999) . BM cells enriched for early progenitors were infected with either FMEV-T/A, FMEV-TSw/A or control FMEV-GFP retroviral pseudotypes. Infection frequencies were comparable for all vectors (Figure 1b and data not shown). Western blot analysis of FMEV-T/A or FMEV-TSw/A-transduced cells confirmed the expression of both proteins with the expected molecular weight (Figure 1c) .
To determine the effect of TEL/AML1 on normal hematopoiesis, BM cells transduced with either the FMEV-T/A or control vector were transplanted into irradiated mice. At different time points starting at three months after transplantation, hematopoietic organs (BM, spleen, and blood) were analysed for various parameters, including size and cellularity, leukocyte counts and hematocrit values. No gross differences between mice receiving BM cells transduced with FMEV-T/A or with FMEV-GFP were observed in any of these organs (data not shown). FACS analysis was performed on BM cells to determine the engraftment frequency of transduced and nontransduced donor cells and lineage distribution. GFP positive cells (T/A þ fraction) were detectable in all FMEV-T/A transduced mice (ranging from 0.6 to 19%, median 8.2%, n ¼ 13) and no significant difference in lineage distribution (i.e. myeloid (CD11b), erythroid (TER119), and T-(CD3) and B-lymphoid (CD19 or B220)) was observed in comparison to the nontransduced population (T/A-fraction) (Figure 1d ). These results demonstrate that expression of TEL/AML1 is compatible with transplantation of long-term hematopoietic stem cells (HSC), giving rise to all hematopoietic lineages. Furthermore, none of the lineage-specific compartments appear to be preferentially stimulated or suppressed by TEL/AML1 expression.
TEL/AML1 impairs differentiation of the B-cell compartment
As t(12;21) is associated with a B-precursor ALL, the number of T/A þ transduced cells in the spleen and blood was determined, which generally contain from 30 to 60% B-cells in the nucleated cell fraction. Strikingly, the percentage of T/A þ cells in the blood was consistently lower than that observed in BM by a mean factor of 0.2470.18 (n ¼ 8). This contrasts sharply to control GFP mice, where the incidence of transduced cells in the blood are generally equivalent or even higher to the levels observed in BM by an average factor of 1.570.68 (n ¼ 11; Po0.001). Similar reductions were observed in the spleen (data not shown.) Notably, a TEL/AML1 transforms progenitor compartment M Fischer et al reduction was observed in all lineages, including myeloid. The most obvious explanation for this observation is that T/A þ transduced cells rarely leave the BM or thymus to enter the periphery, suggesting that either differentiation, maturation, or egression may be impaired. The B-cell compartment in the BM was thus more closely examined. Distinct differentiation stages of B-cell development can readily be assessed using antigen marker expression (Hardy et al., 1991) . We have previously shown that expression of the AML1/ETO protein, the fusion product of the AML-associated t(8;21), inhibits the transition of immature B-cells to a mature phenotype, characterized by a IgM þ /B220 hi immunophenotype (Schwieger et al., 2002) . No equivalent block to differentiation was observed in the T/Atransduced cells. However, a significant two-fold increase in the ratio of pre-and pro-B-cells (IgM (Figure 2b) . Thus, although B-cell differentiation is not blocked by T/A, there is a significant left shift toward less differentiated forms. This could be the consequence of a number of different mechanisms, including a 'slowing' of the differentiation process (more cell cycles associated with 'self-renewal' and less cycles associated with changes in the differentiation status), decreased proliferation capacity of the more differentiated cell types, or the induction of apoptosis in these cells.
TEL/AML1 does not increase B-cell colony formation in vitro
To differentiate between these different hypotheses, colony assays were performed. BM cells were infected with FMEV-T/A and FMEV-GFP under conditions that enrich for B-cell progenitors (IL7, FL, and SCF), sorted for GFP expression, and scored for cloning capacity under the same conditions. FACS analysis was performed to evaluate GFP expression and to confirm the B-cell immunophenotype (B220 þ /CD34 þ ) of the cells within the colonies (Figure 2c ). Strikingly, the number of colonies generated from T/A þ sorted cells was reduced by a factor of 10, as compared to control GFP þ cells (Figure 2d ). Furthermore, replating experiments did not reveal any subpopulation with increased self-renewal capacity or with increased colony size. To rule out the possibility that cell sorting introduced a bias into the assay, the experiment was repeated three times with unsorted cells and the percentage of GFP þ cells in each plate was determined after colony formation ( Figure 2d and data not shown). Consistent with the interpretation that T/A inhibits colony growth, the percentage of T/A þ cells dropped with each plating. Morrow et al. (2004) have recently reported an increase in both colony number, colony size, and replating efficiency when T/A-infected progenitors derived from fetal liver cells were plated under the same conditions. We thus performed this experiment using fetal livers cells sorted for cKit expression. However, in agreement with our BM cell assay, colony growth of T/A-infected B-cell derived from fetal liver was rather impaired and not stimulated (data not shown).
As an enrichment of early B-cell progenitors expressing T/A was observed in vivo, we predict that lineage commitment into this compartment is not blocked but that differentiating forms have an impaired proliferation capacity, and are thus unable to form colonies under these in vitro conditions. The drastically reduced levels of T/A þ cells in the blood as compared to the BM suggest that other lineages may also be affected. Thus, the myeloid compartment in the BM was also more closely examined. During granulocytic differentiation, expression levels of the Gr1 antigen increase. Analysis of the Gr1 expression levels revealed a 58% reduction in the mean levels of Gr1 expressed as compared to nontransduced cells (Figure 3a , b). The observed decrease in the mean levels of Gr1 was very subtle, however, as compared to the effect observed in mice expressing AML/ETO, in which Gr1 levels were reduced by a factor of 6.5-fold (Schwieger et al., 2002) . Mice deficient in the Icsbp gene encoding interferon factor 8 (IRF8) show enhanced proliferation of the myeloid compartment, resembling a chronic myelogenous leukemia (Holtschke et al., 1996) . We thus transduced BM cells from these mice to determine if the effect on myelopoiesis would be amplified. The percentage of T/A transduced cells in the BM was similar to that observed in B6 wt BM (ranging from 2 to 44%, median 7.2%, n ¼ 8), with a similar striking reduction of T/A þ cells in the spleen and blood. No gross differences in the lineage distribution was observed (data not shown), but the mean level of Gr1 expression in the T/A þ subpopulation was slightly reduced, again reflecting impaired granulocytic differentiation and maturation. Taking advantage of two mice with greater than 40% T/ A transduced cells and the fact that up to 80% of the B6 Icsbp À/À BM compartment is myeloid, we could readily observe that T/A þ Icsbp À/À BM contains significantly less mature segmented neutrophils, in contrast to GFP þ Icsbp À/À BM transplantation controls (Figure 3c ). Notably, no gross accumulation of myeloblasts was observed. Interestingly, a high incidence of abnormal megakaryocytes was also observed, primarily resembling 'micromegakaryocytes' (Figure 3c ). This is not a normal characteristic of the Icsbp À/À mice (Holtschke et al., 1996 ; JL, unpublished observations), but has also recently been reported in the BM of Runx1 þ /À and conditional Runx1 À/ À mice (Ichikawa et al., 2004) .
TEL/AML1, but not the PTD mutant, increases the self-renewal capacity of myeloid progenitors
To determine if the reduction in mature granulocytic forms reflected a subtle left shift in the myeloid differentiation status coupled with increased cloning capacity, colony assays supporting myeloid and erythroid differentiation were performed on B6 wt BM cells sorted for GFP expression after infection with either FMEV-T/A, FMEV-TSw/A or control FMEV-GFP. Although no significant differences in the colony numbers generated from GFP-, T/A-, or TSw/Atransduced BM cells were observed in the first plating, replating cells harvested from the plates revealed significant differences between T/A þ and the two other populations. Although both GFP-and TSw/A-transduced cells failed to generate colonies after the third plating, colony-forming cells were still present in T/Atransduced cells after five rounds of plating, albeit with reduced frequency after the second plating (Figure 3d ). Cytospins and FACS analysis of cells dispersed from the colonies after replating confirmed that the T/A þ colonies were composed of erythroid, granulocytic, and monocytic progenitors, in contrast to the cells from GFP þ and TSw/A þ colonies that contained exclusively end-differentiated macrophages and mast cells (Figure 3e ). Taken together, these results demonstrate that TEL/AML1 also imposes subtle but significant impairment of myeloid differentiation and that the PTD domain of T/A is essential for its function and cannot be replaced by another oligomerization domain.
Expansion of an Sca1 þ /Kit hi compartment within the T/A þ transduced population Effects in both the early myeloid and lymphoid progenitors within the T/A-transduced population suggested that an early multipotent compartment may be also affected in these mice. We thus examined BM cells for expression of the stem-cell antigen Sca1 and the cKit receptor. A prominent population expressing Sca1 þ /cKit hi antigens could be observed in all T/Atransduced BM cells, which was coincident with high levels of GFP (Figure 4a ). Gating on the high GFP population allowed us to confirm that these cells did not express any lineages markers (e.g. B220, CD19, Gr1, TER119, and CD3), with the exception of moderate levels of CD11b (Figure 4b and data not shown) . Previous studies have demonstrated that the Sca1 þ / cKit hi /Lin À population encompasses the HSC and multipotential progenitor (MPP) compartments, normally present at a frequency of circa 0.02% in the BM ). CD11b expression is detected in HSC/MPP stimulated to proliferate, such as after treatment with 5-fluorouracil (Randall and and has also been associated with the short-term repopulating HSC population (Morrison et al., 1997) . Significantly, however, the T/A þ /GFP hi cells did not express Flt3 (Figure 4b) , a receptor present on shortterm but not long-term repopulating cells (Christensen and Weissman, 2001) .
The incidence of this Sca1 þ /Kit hi population within the T/A þ population varied between mouse to mouse, ranging from 1 to 7% in B6 wt mice and from 3 to 80% in B6-Icsbp À/À mice (Table 1) . Taking into account the frequency of transduced cells, the incidence of this population within the whole BM is on the average 16-fold higher than the normal Sca1 þ /Kit hi /Lin À pool in B6 wt mice, which occurs at a frequency of circa 0.02% -and could be found at levels as high as 600-fold above the normal frequency in B6 Icsbp À/À mice when assayed at one year after transplantation (Table 1) . Interestingly, this T/A þ Sca1 þ /cKit hi subpopulation could also be found at unexpectedly high frequencies in the blood, making up approximately 20% of the poorly represented TA þ population in this organ (Figure 4f and data not shown). Giemsa staining of cytospins of the GFP hi sorted cells revealed a relatively homogenous population of cells with a high nucleus to cytoplasm ratio, roundish nuclei, intermediate cytoplasmic basophilia, and lack of cytoplasmic granules, consistent with the morphology of HSC/MPP (Figure 4d ). Taking advantage of their unique morphology and high GFP expression, and thus easy detection in BM sections, we also sought to determine their localization in the BM. However, arguing against these cells being HSC, no accumulation of cells with GFP immunopositivity was observed on endosteal surfaces, the postulated stem cell niche (Gong, 1978) , but GFP hi cells could be observed disseminated throughout the BM tissue (Figure 4e) . Furthermore, this cell population contained only a low incidence (circa 0.03%) of long-term repopulating cells, as determined by serial dilution of GFP hi -sorted cells and retransplantation.
Expression profiles of the T/A þ /GFP hi population
In parallel to the analysis above, a survey of the gene expression profile of T/A þ /GFP hi (Sca þ /cKit hi ) population by RT-PCR was performed to better characterize this population. This analysis revealed high expression levels of the TEK gene, previously shown to be restricted to the HSC/MPP compartment, as well as expression of other transcription factors shared by the HSC compartment and other lineages (e.g. NF-E2, PU.1, GATA-2, and GATA-3), but not transcription factors specific to a committed lineage (e. 
This analysis supports the hypothesis that the Sca1
þ / cKit hi population is an early progenitor. To gain insight into the mechanism of transformation, we performed semiquantitative RT-PCR to compare the expression levels of a various genes in nontransduced and T/Atransduced Sca1 þ /cKit hi /Lin À cells. Serial dilutions of cDNA were performed and the expression levels relative to HPRT and TEK were compared. No significant increase in the transcript levels of genes encoding the polycomb factors bmi1 or mel-18 that regulate Hox gene expresssion, or encoding Wnt signaling pathway members (b-and g-catenin) were detected, although these have been implicated as target genes of oncogenes that increase HSC self-renewal (Lessard and Sauvageau, 2003; Smith et al., 2003; Muller-Tidow et al., 2004) (Figure 5b and data not shown). Furthermore, we observed no differences in the level of the Mcl1 or Bclx genes, encoding bcl2-like antiapoptotic proteins, nor in the level of transcripts encoding the PU.1 transcription factor, which has been postulated to be a target gene of AML1 (Okada et al., 1998) and a critical factor for the regulation of both myeloid and B-lymphoid differentiation (Tenen et al., 1997; Schebesta et al., 2002) (Figure 5b and data not shown) . Thus, the mechanism by which TEL/AML1 transforms this early compartment is not clear.
Discussion
Modeling human leukemias in mouse models have become a powerful tool to understand the transforming events during leukemogenesis (Bernardi et al., 2002 ). In the model described here to investigate the role of t(12;21) in ALL, we show that TEL/AML1 expression induces a striking expansion of an early Sca1 þ /Kit hi / CD11b med MPP compartment in vivo and has a specific Figure 6 , others are clearly distinct and thus demonstrate that intrinsic properties of the TEL/AML1 fusion protein dictate the phenotype of the leukemia, to which it is associated. Consistent with its association with precursor B-cell ALL, TEL/AML1 perturbed B-cell differentiation, resulting in a four-fold increase in the proportion of pro-B-cells in the B-cell compartment as compared to nontransduced cells. The impaired B-cell differentiation was also evident by the relatively low levels of mature lymphoid cells carrying TEL/AML1 in the blood and spleen. However, it is important to note that whereas differentiation is impaired by TEL/AML1, it is not blocked. This is in accord with data on cord blood preleukemic clones in which mature B-cells (kappa or lambda light chain positive) with TEL/AML1 were present along with an expanded B-progenitor population (Mori et al., 2002) . Somewhat surprisingly, this shift toward less differentiated B-cells was not reflected in an increase in B-cell colony numbers in vitro. Indeed, there was a striking decrease in the number of colonies arising from T/A-transfected cultures. A likely explanation of these results is not that there is a reduction in the number of colony-forming-cells but rather that proliferation of the maturing B-cells is inhibited by T/A in vitro and also, but to a lesser degree, in vivo. Our findings are consistent with those of Tsuzuki et al. (2004) , and demonstrate that the reduction in B-cell clone numbers that they observed is not due to a unique property of the BALB/C mouse strain, which is predisposed to B-cell and myeloid neoplasias (Elefanty and Cory, 1992; Zhang et al., 2001) . Significantly, the perturbation of the B-cell lineage observed in T/A mice is distinct to that observed in AML1/ETO mice (Schwieger et al., 2002) and for that observed in mice deficient for AML1 (Putz et al., 2005) , demonstrating that an intrinsic function of T/A is responsible for this altered phenotype.
The most striking observation of the T/A-transduced fraction was expansion of a Sca1 þ /Kit hi /CD11b med cell pool. As early as 18 weeks after transplantation, a more than 100-fold increase of this population relative to the nontransduced population in B6 wt mice was observed. We investigated several parameters to determine the cell type of this expanded compartment, including morphology, immunophenotype, repopulation capacity, and gene expression pattern. Based on these criteria, we conclude that this cell population is an MPP, able to differentiate into erythroid and myeloid cells (including granulocytes, monocytes, and mast cells). We were unable to confirm its ability to differentiate into the B-lineage in vitro, but this may be due to the fact that T/A expression inhibited in vitro colony-formation of B-cell progenitors. The ability of these cells to form colonies of multiple lineages rules out the possibility that these cells are mast cell progenitors, which are also Sca1 þ /Kit hi . Importantly, these cells also have high recloning capacity, as determined by serial replating assays and are detectable in the blood of T/A-transduced mice at relatively high frequencies. It is thus tempting to speculate that they may represent the expanded pool of cells carrying the t(12;21) that are transferred from one monochorionic twin to the other in utero and readily detectable in umbilical cord blood samples (Mori et al., 2002; Greaves et al., 2003) . Due to the increased selfrenewal capacity of these cells, this cell pool may be maintained for many years, either feeding the expanded B-cell progenitor compartment where secondary lesions may occur or, alternatively, incurring secondary mutations that specifically affect B-cell differentiation.
Expansion of this compartment is cell autonomous, and thus can be due to an intrinsic change in the HSC/ MPP that either inhibits apoptosis, promotes selfrenewal or impairs differentiation. We have examined the transcript levels for several genes implicated in blocking apoptosis and promoting self-renewal of the HSC, or regulating myeloid and B-cell differentiation, but have not identified any significant changes in these gene expression levels. The expansion of a Sca1 þ /Kit hi compartment has also been reported in BM of AML1
À/À and AML1 þ /À mice (Ichikawa et al., 2004; Sun and Downing, 2004) , and an AML1/ETO mouse model (de Guzman, 2002) . However, as the populations identified in these models do not express CD11b, we postulate that the expanded population in the T/A mice is unique.
A subtle effect on myeloid differentiation after T/A expression was also observed, as evidenced by reduced levels of mature T/A-transduced myeloid cells in the blood. Consistent with runx þ /À , runx1 À/À (Ichikawa et al., 2004; Sun and Downing, 2004; Growney et al., 2005) and AML1/ETO mice (J Lo¨hler, unpublished results) impaired megakaryopoiesis was also observed in the BM of T/A-transduced mice. However, the subtle effect on granulopoiesis is in striking contrast to the profound effect that AML1/ETO has on expanding the early myeloid compartment (de Guzman, 2002; Higuchi et al., 2002; Schwieger et al., 2002) . It has been predicted that this effect of AML1/ETO is a consequence of sequestering C/EBPa, an important regulator of myeloid differentiation (Westendorf et al., 1998; Pabst et al., 2001) . Further studies are necessary to determine why this would be a unique characteristic of AML1/ETO not shared by TEL/AML1, as the RHD has been implicated in this repression (Petrovick et al., 1998) .
To define the domains of TEL/AML1 necessary for disturbing the fine controls of differentiation and selfrenewal, we showed that the PTD cannot be functionally replaced with another oligomerization domain. These experiments do not rule out that oligomerization per se is not important for TEL/AML1 function, but rather show that the PTD sequences must have an additional function, such as the direct recruitment of transcriptional corepressors or sequestering of wt TEL (McLean et al., 1996; Fenrick et al., 2000) . Although immunoprecipitation analysis confirmed that TSw/A mutant retained its capacity to bind the corepressor Sin3A and histone deacetylase 3 (S Horn, unpublished results), quantification using this Figure 6 Schematic representation of the oncogenic effect of RUNX1 mutations on hematopoietic differentiation. The effect of TEL/ AML1 (T/A; dark shaded triangles), AML1/ETO (A/E, lightly shaded triangles), or AML1 deficiency (AÀ/À, white triangles) on myeloid and lymphoid differentiation is indicated by triangles, where the width denotes the relative size of the cell pool at the corresponding differentiation stage. Consistent with the leukemias in which they are found, TEL/AML1 and AML1/ETO expression differentially effect B-cell and myeloid differentiation, respectively. Interestingly, all mouse models affect the HSC/MPP compartment and megakaryocyte differentiation; however, the extent and stage at which an early HSC/MPP compartment is expanded appears to differ between the three models. T-cell maturation is also blocked in all three mouse models, but only in the case of AML1 deficiency has the exact stage been characterized (Hayashi et al., 2000; Ichikawa et al., 2004) TEL/AML1 transforms progenitor compartment M Fischer et al technique is difficult. Thus, deletion of the PTD may compromise the repressor levels recruited to key promoters necessary to interfere with the differentiation program. Alternatively, the PTD may be required for oligomerizing with wt TEL, thereby sequestering the purported tumor suppressor activity of TEL (Fenrick et al., 2000; van Rompaey et al., 2000; Irvin et al., 2003) . Further work is required to define the importance of PTD in the TEL/AML1-induced pathogenesis. Despite the disproportionate high frequency of early hematopoietic progenitors with high self-renewal capacity in the BM over a one-and-half year observation period, we did not observe any overt signs of leukemia induction. This is in agreement with the relatively late age at which pre-B ALL associated with t(12;21) may occur in children (up to 10 years), despite the high frequency at which the translocation occurs in utero (Mori et al., 2002) . A previous study has demonstrated that loss of the Ink4a locus, containing the genes for the tumor suppressors p16 and p14 ARF , can synergize with TEL/AML1 expression to induce leukemia (Bernardin et al., 2002) . However, the long latency of the disease in this scenario suggests that other mutations are necessary. Our model is thus well suited to test other players in the multistep process of leukemogenesis, thus identifying useful targets for therapeutic interventions.
Materials and methods
Retroviral vectors and generation of infectious pseudotyped virus particles
The TEL/AML1 coding region was inserted into the NotI site of plasmid pSF91-I-eGFP-PRE (R780) containing the FMEVbased retroviral vector (Schwieger et al., 2002) to generate FMEV-T/A (R934). To exchange the PTD domain with an unrelated coiled-coiled oligomerization domain, the dimerizer domain of EB1/Zebra of the Epstein-Barr virus was used by replacing the TEL portion of T/A with the corresponding region of TELDBsw(193-244)EB1 (Lopez et al., 1999) using shared restriction sites. Retroviral pseudotypes were generated as previously described (Schwieger et al., 2002) .
Infection and BM transplantion
C57BL/6J-Ly5.1 mice were used as recipients for all BM transplantations. BM cells were isolated from tibiae and femura of either untreated C57BL/6J-Ly5.2 (B6 wt) or from Icsbp
) mice that received i.p. injections of 5-fluorouracil (150 mg/kg) 4 days prior to isolation. Before infection, BM cells from B6 wt mice were enriched for progenitors by depletion of Lin neg cells using a Mouse Lineage Panel (BD PharMingen, Hamburg, Germany). Infections and transplantations were carried out as previously described (Schwieger et al., 2002; Li et al., 2003) . To determine incidence of LTR-HSC, BM cells from two transplanted mice were pooled and sorted on basis of GFP hi /cKit hi /Sca1 þ and injected i.p. into sublethally irradiated mice (2 Gray). Five mice were injected per cell dilution, which was supplemented with Lin pos cells to a total cell number of 5 Â 10 5 . At 12 weeks after transplantation, the percentage of long-term repopulating cells was calculated from the number of mice positive for GFP expression applying the Poisson distribution; a 10% cloning efficiency was assumed. All animal experiments were approved by the Hamburg Office of Health (Permit No. 04/2000) .
Western blot analysis
Transfected Phoenix cells or Jurkat cells were lysed in Nonidet s P40 lysis buffer containing protease inhibitors. Cell extracts were analysed by sodium dodecyl sulfate polyacrylamide gel electrophoresis and Western blot analysis as described previously (Meyer et al., 1998) . To detect protein expression, a 1 : 1000 dilution of the polyclonal anti-AML1 (N-20), anti-TEL (N-19) , or anti-GFP (FL) antibody (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) or a 1 : 5000 dilution of the monoclonal anti-alpha-Tubulin (clone DM1A, Merck Biosciences Ltd, Nottingham, UK) antibody was used. The bound antibody was detected with the appropriate secondary antibody conjugated with horseradish peroxidase and visualized using the enhanced chemiluminescence system (ECL, Amersham, Buckinghamshire, UK).
Flow cytometry
For lineage marker analysis, single-cell suspensions were prepared from hematopoietic tissues after lysis of erythroid cells with PharmMLyset (BD PharMingen) and incubated at 41C for 30 min in PBS containing 2% BSA with PE-, Allophycocyanin-, or CyChromt-conjugated mAbs (BD PharMingen). Nonspecific binding of mAbs was prevented by preincubation with Fc Blockt (BD PharMingen). Only vital cells as determined by exclusion of propidium iodide were measured. Cells were washed twice with PBS containing 2% BSA and applied for analysis on a FACSCalibur (BD Biosciences, Heidelberg, Germany). An Aria Cell Sorter (BD Biosciences) was used to sort transduced cells prior to colony assays and for analysis of the cKit hi /Sca1 þ populations.
In vitro colony-forming assays
Colony assays were performed on either freshly infected BM cells or from GFP pos BM cells isolated from transplanted mice. Single-cell suspensions (1 Â 10 4 , 5 Â 10 4 or 10 5 /ml) were plated in triplicates in methylcellulose supplemented with either cytokines supporting myeloid differentiation (MethCultt GF M3434, StemCell Technologies, Meylan, France) or B-cell differentiation (MethCultt M3231) supplemented with 20 ng/ ml IL7, 10 ng/ml Flt3 ligand (FL) and 100 ng/ml stem cell factor (SCF) and incubated at 371C. Individual colonies were scored nine days postplating. Cells were replated in triplicates at densities of 1 Â 10 4 cells/ml. Replating was performed at intervals of 7 days. At each time point, the immunophenotype and morphology of the cells was determined by FACS analysis and cytospins stained by the method of Giemsa (Sigma, Deisenhofen, Germany).
Histologic and immunohistologic methods
Histological inspection of hematopoietic tissue was performed as previously described (Schwieger et al., 2002) . For immunohistochemical detection of GFP and myeloperoxidase, a twostep immunoenzymatic method was employed using rabbit polyclonal antibodies from Abcom Ltd (Cambridge, UK) and DakoCytomation (Hamburg, Germany), respectively. Briefly, antigen retrieval was achieved by autoclaving deparaffinated sections for 30 min in a citrate-based demasking solution (Antigen Retrieval Citra Solution, BioGenex, San Ramon, CA, USA). After incubation with primary antibodies, speci-TEL/AML1 transforms progenitor compartment M Fischer et al fically bound antibodies were detected using a highly sensitive phosphatase and polymer conjugated anti-rabbit IgG detection system (Histofine, Nuchirei, Tokyo, Japan). Phosphatase activity was revealed with naphthol-AS-BI-phosphate and New Fuchsin (DakoCytomation) as substrate.
Semiquantitative RT-PCR analysis RNA was isolated using RNeasy (Qiagen, Valencia, CA, USA) and first strand cDNA was generated from 1 mg of total RNA using Avian Myeloblastosis Virus reverse transcriptase (Promega, Madison, WI, USA) and a random primer p(dN) 6 (Boehringer, Mannheim). To compare expression patterns of cKit hi /Sca1 þ /Lin neg cells, 10 4 cells were sorted directly into 500 ml of Trizol (Invitrogen, Carlsbad, CA, USA) in the presence of MS2 Phage RNA (Roche, Mannheim). Serial dilution (1 : 3) of cDNA was performed to quantify transcript levels. PCR reactions were performed using primers crossing intron-exon boundaries. Primers and conditions used for the analysis can be obtained upon request.
Abbreviations ALL, acute lymphoblastic leukemia; AML, acute myelogenous leukemia; AML1, protein encoded by RUNX1; A/E, AML1/ ETO; CBF, core-binding factor; eGFP, enhanced gree fluorescent protein; IL3, interleukin-3; IL7, interleukin-7; PTD, pointed domain; RHD, runt homology domain; SCF, stem cell factor; T/A, TEL/AML1; TAD, transactivating domain.
